MedPath

CER-001

Generic Name
CER-001
Drug Type
Biotech

Overview

CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.

Background

CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase 3
Terminated
Posted: 2016/03/03
Sponsor:
Cerenis Therapeutics...
Phase 2
Completed
Posted: 2015/06/29
Sponsor:
Cerenis Therapeutics...
Phase 2
Completed
Posted: 2012/01/24
Sponsor:
Cerenis Therapeutics...

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath